Tofacitinib con Fármacos Modificadores de la Enfermedad Convencionales en Pacientes Chinos con Artritis Reumatoide: Resultados Informados por los Pacientes desde un Ensayo Fase 3 Controlado Aleatorizado
Int J Rheum Dis 2018; 21(2):402–14
This Chinese sub-population of patients with RA from ORAL Sync reported significant improvements in patient-reported outcomes (PROs), which were maintained up to 12 months from tofacitinib (TOF) treatment initiation. ORAL Sync was a randomised, Phase 3 study investigating TOF therapy in combination with csDMARDs in patients with active RA who had previously had an inadequate response to csDMARDs. To date, this is the only Phase 3 study of TOF in patients from China with RA. This analysis include...